Product Code: ATFB0011015
Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.
This report provides the current prevalent population for AF across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Canada, Australia, Netherlands, Argentina, Russia, China and South Korea) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for AF include:
- Hypertension
- CHF/ CAD and other structural cardiac diseases
- Diabetes
- Mitral Stenosis / other valvular disorders
- COPD
- Stroke
- Rheumatic Heart Disease
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Able to quantify patient populations in global AF's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of AF and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on AF's prevalent population.
- Identify sub-populations within AF which require treatment.
- Gain an understanding of the specific markets that have the largest number of AF patients.
Coverage
- U.S.
- United Kingdom
- France
- Germany
- Italy
- Spain
- Japan
- U.K.
- China
- India
|
- Turkey
- Canada
- Australia
- Netherland
- Argentine
- Russia
- Korea
- Mexico
|
Table of Contents
- List of Tables and Figures
- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key Co-morbid Conditions/ Features Associated with the Disease
- Methodology for Quantification of Patient Numbers
- Additional data available on request
- Top-Line Prevalence for Atrial Fibrillation
- Main Type and Cardiac Features of AF
- AF Main Type Classification
- Associated Cardiac Conditions of AF
- Type of AF Treatment
- Abbreviations used in the Report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix
List of Figures:
- AF prevalence rates for 2015
- ESC Guidelines for Management of AF
List of Tables
- Prevalence of AF, total (000s)
- Prevalence of AF, males (000s)
- Prevalence of AF, females (000s)
- Classification of AF by duration of episode, total (000s)
- Type of AF classified by valvular or non-valvular, total (000s)
- AF by 5 year incidence of stroke event, total (000s)
- AF classified by type of ischaemic stroke mechanism, total (000s)
- Prevalence of hypertension in AF patients, total (000s)
- Prevalence of CAD in AF patients, total (000s)
- Prevalence of valvular heart disease in AF patients, total (000s)
- Prevalence of left ventricular hypertrophy in AF patients, total (000s)
- AF patients taking anti-arrhythmic drugs, total (000s)
- AF patients taking Vitamin K antagonists, total (000s)
- AF patients taking anti-platelet therapy, total (000s)
- AF patients with a pacemaker/ ICD implant, total (000s)
- Catheter ablation in AF patients, total (000s)
- Abbreviations and Acronyms used in the report
- USA Prevalence of AF by 5-yr age cohort, males (000s)
- USA Prevalence of AF by 5-yr age cohort, females (000s)
- France Prevalence of AF by 5-yr age cohort, males (000s)
- France Prevalence of AF by 5-yr age cohort, females (000s)
- Germany Prevalence of AF by 5-yr age cohort, males (000s)
- Germany Prevalence of AF by 5-yr age cohort, females (000s)
- Italy Prevalence of AF by 5-yr age cohort, males (000s)
- Italy Prevalence of AF by 5-yr age cohort, females (000s)
- Spain Prevalence of AF by 5-yr age cohort, males (000s)
- Spain Prevalence of AF by 5-yr age cohort, females (000s)
- United Kingdom Prevalence of AF by 5-yr age cohort, males (000s)
- United Kingdom Prevalence of AF by 5-yr age cohort, females (000s)
- Brazil Prevalence of AF by 5-yr age cohort, males (000s)
- Brazil Prevalence of AF by 5-yr age cohort, females (000s)
- Japan Prevalence of AF by 5-yr age cohort, males (000s)
- Japan Prevalence of AF by 5-yr age cohort, females (000s)
- India Prevalence of AF by 5-yr age cohort, males (000s)
- India Prevalence of AF by 5-yr age cohort, females (000s)
- Mexico Prevalence of AF by 5-yr age cohort, males (000s)
- Mexico Prevalence of AF by 5-yr age cohort, females (000s)
- Turkey Prevalence of AF by 5-yr age cohort, males (000s)
- Turkey Prevalence of AF by 5-yr age cohort, females (000s)
- Canada Prevalence of AF by 5-yr age cohort, males (000s)
- Canada Prevalence of AF by 5-yr age cohort, females (000s)
- Australia Prevalence of AF by 5-yr age cohort, males (000s)
- Australia Prevalence of AF by 5-yr age cohort, females (000s)
- Netherlands Prevalence of AF by 5-yr age cohort, males (000s)
- Netherlands Prevalence of AF by 5-yr age cohort, females (000s)
- Argentina Prevalence of AF by 5-yr age cohort, males (000s)
- Argentina Prevalence of AF by 5-yr age cohort, females (000s)
- Russia Prevalence of AF by 5-yr age cohort, males (000s)
- Russia Prevalence of AF by 5-yr age cohort, females (000s)
- China Prevalence of AF by 5-yr age cohort, males (000s)
- China Prevalence of AF by 5-yr age cohort, females (000s)
- South Korea Prevalence of AF by 5-yr age cohort, males (000s)
- South Korea Prevalence of AF by 5-yr age cohort, females (000s)
